Description
Super tastylia (Tadalafil + Dapoxetine) 20 mg + 60 mg
Super tastylia is a combination product identified here as containing tadalafil and dapoxetine. Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction, while dapoxetine is a selective serotonin reuptake inhibitor (SSRI) developed for premature ejaculation. The combination has been studied for men with both conditions, but the verified regulatory status of this specific fixed-dose product may vary by country and is not established here as a standard approved medicine.
Active Ingredient and Medicine Class
Tadalafil belongs to the PDE5 inhibitor class. It supports erectile function by enhancing blood flow in the penis during sexual stimulation.
Dapoxetine is a short-acting SSRI. It is used for premature ejaculation in markets where it is approved.
Established Medical Uses
Tadalafil is established for erectile dysfunction and, in some jurisdictions, other urologic or vascular indications depending on the product label. Dapoxetine is established for premature ejaculation where approved by regulators such as the European Medicines Agency.
Clinical studies have evaluated the combination of dapoxetine and tadalafil in men with premature ejaculation, including men who also have erectile dysfunction, but this does not by itself confirm approval of the fixed-dose combination product.
How It Works
Tadalafil inhibits PDE5, which helps preserve cyclic GMP and promotes smooth muscle relaxation and increased penile blood flow during sexual stimulation.
Dapoxetine increases serotonin signaling by blocking serotonin reuptake. In clinical use, this can help delay ejaculation.
Important Safety Information
Tadalafil is contraindicated with organic nitrates because the combination can cause dangerous drops in blood pressure. Important cautions also include use with alpha-blockers, antihypertensives, alcohol, and strong CYP3A4 inhibitors. Tadalafil has warnings related to priapism, sudden visual loss, and sudden hearing loss.
Dapoxetine should not be used with potent CYP3A4 inhibitors and should be avoided with alcohol in official European product information. It may also increase the risk of dizziness, fainting, and low blood pressure, especially when combined with other medicines that can lower blood pressure. As a serotonin reuptake inhibitor, it may contribute to serotonergic adverse effects when combined with other serotonergic drugs.
Possible Side Effects
Common adverse effects reported with tadalafil include headache, flushing, dyspepsia, nasal congestion, back pain, and muscle pain. Important serious reactions include priapism, significant blood pressure lowering, visual changes, and hearing changes.
Common adverse effects reported with dapoxetine include nausea, headache, dizziness, diarrhea, insomnia, and sometimes fainting or orthostatic symptoms. Serious reactions may include syncope and serotonin-related toxicity when interacting medicines are used.
Scientific Evidence
Human studies have examined dapoxetine with tadalafil in men with premature ejaculation, including those with comorbid erectile dysfunction. A randomized crossover pharmacokinetic study found no major pharmacokinetic interaction between dapoxetine and tadalafil. Other clinical trials suggest the combination may improve ejaculatory outcomes in selected men, but these studies are relatively small and do not establish the fixed-dose product as universally approved or preferable.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet, product label, or an individual professional assessment.
Medical Sources
- European Medicines Agency — Priligy referral page and Summary of Product Characteristics materials: https://www.ema.europa.eu/en/medicines/human/referrals/priligy
- DailyMed / FDA label — Tadalafil tablet prescribing information: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc14daa3-cae9-4751-9034-b0e9c18054b4
- Dresser MJ et al. — “Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors” — International Journal of Impotence Research, 2006 — https://pubmed.ncbi.nlm.nih.gov/16307008/
